MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 154 participants.

Also called NCT05409989

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 154 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05409989
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05409989. Allocation not applicable; no masking; primary purpose treatment. Start 2022-09-20 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
Condition
Intracranial Aneurysm
Intervention (Device)
FRED™ X™
Lead sponsor
Microvention-Terumo, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05409989
Content hash
53c260a959d603faaea8d4ac551d1c54947a1d8ab7fe2906f715a9afc61223ee